Effects of FasL expression in oral squamous cell cancer

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 1, 2013, Pages 281-285

  Fang, Li ^a   Sun, Lin ^a   Hu, Fang Fang ^a   Chen, Qiao Er ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Fas; FasL; Lymphatic metastasis; Oral SCC

Indexed keywords

EID: 84877113811     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.1.281     Document Type: Article

References (28)

1. Bennett MW, O'connell J, O'sullivan GC, et al (1999). Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer. Gut, 44, 156-62.
2. Bozdogan N, Bozdogan O, Pak I, et al (2010). Fas, Fas ligand, tumor infiltrating lymphocytes, and macrophages in malignant melanoma: an immunohistochemical study. Int J Dermato, l49, 761-7
3. Cai Z, Yang F, Yu L, et al (2012). Activated T cell exosomes promote tumor invasion via Fas signaling pathway. J Immunol, 188, 5954-61.
4. Chen Q, Samaranayake LP, Zhen X, et al (1999). Up-regulation of Fas ligand and down-regulation of Fas expression in oral carcinogenesis. Oral Oncol, 35, 548-53
5. de Camargo Cancela M, Voti L, Guerra-Yi M, et al (2010). Oral cavity cancer in developed and in developing countries: population-based incidence. Head Neck, 32, 357-67
6. Ehrenschwender M, Wajant H (2009). The role of FasL and Fas in health and disease. Adv Exp Med Biol, 647, 64-93
7. Gomes TS, Oshima CT, Segreto HR, et al (2011). The extrinsic apoptotic signaling pathway in gastric adenocarcinomas assessed by tissue microarray. Pathol Res Pract, 207, 613-7.
8. Gryko M, Guzinska-Ustymowicz K, Pryczynicz A, et al (2011).Correlation between Fas and FasL proteins expression in normal gastric mucosa and gastric cancer. Folia Histochem Cytobiol, 49, 142-7
9. Hadzi-Mihailovic M, Raybaud H, Monteil R, et al (2009).Expression of Fas/FasL in patients with oral lichen planus. J Buon, 14, 487-93
10. Hub H (1997). Fas-mediated apoptosis in tumor formation and defense. Biol Chem, 378, 1405-12.
11. Hueber A, Welsandt G, Jordan JF, et al (2002). Characterization of CD95 ligand(CD95L) induced apoptosis in human tenon fibroblasts. Exp Eye Res, 75, 1-8.
12. Ibrahim R, Frederickson H, Parr A, et al (2006). Expression of FasL in squamous cell carcinomas of the cervix and cervical intraepithelial neoplasia and its role in tumor escape mechanism. Cancer, 106, 1065-77.
13. Ji J, Wernli M, Buechner S, et al (2003). Fas ligand downregulation with antisense oligonucleotides in cells and in cultured tissues of normal skin epidermis and basal cell carcinoma. J Invest Dermatol, 120, 1094-9.
14. Kassouf N, MH (2008). Oral cancer cell lines can use multiple ligands, including Fas-L, TRAIL and TNF-alpha, to induce apoptosis in Jurkat T cells: possible mechanisms for immune escape by head and neck cancers. Oral Oncol, 44, 672-82.
15. Koornstra JJ, de Jong S, Boersma-van Eck W, et al (2009). Fas ligand expression in lynch syndrome-associated colorectal tumours. Pathol Oncol Res, 15, 399-406.
16. Kurita H, Nakanishi Y, Nishizawa R, et al (2010). Impact of different surgical margin conditions on local recurrence of oral squamous cell carcinoma. Oral Oncol, 46, 814-7.
17. Nagata S, Golstein P (1995). The Fas death factor. Science, 267, 1449-56.
18. Narayana N, Gist J, Smith T, et al (2010). Desmosomal component expression in normal, dysplastic and oral squamous cell carcinoma. Dermatol Res Pract, 2010, 649731.
19. Shimonishi T, Isse K, Shibata F, et al (2000). Up-regulation of fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance. Hepatology, 32, 761-69.
20. Tian J, Pan F, Li J, et al (2012). Association between the FAS/FASL polymorphisms and gastric cancer risk: a meta-analysis. Asian Pac J Cancer Prev, 13, 945-51.
21. Töpfer K, Kempe S, Müller N, et al (2011). Tumor evasion from T cell surveillance. J Biomed Biotechnol, 2011, 918471.
22. Wang W, Zheng Z, Yu W, et al (2012). Polymorphisms of the Fas and FasL genes and risk of breast cancer. Oncol Lett, 3, 625-8.
23. Weinberg MA, Estefan DJ (2002). Assessing oral malignancies.Am Fam Physician, 65, 1379-84.
24. Wu W, Wang HD, Guo W, et al (2010). Up-regulation of Fas reverses cisplatin resistance of human small cell lung cancer cells. J Exp Clin Cancer Res, 29, 49-56.
25. Younes M, Schwartz MR, Ertan A, et al (2000). Fas ligand expression in esophageal carcinomas and their lymph node metastases. Cancer, 88, 524-8.
26. Zeytun A, Hassuneh M, Nagarkatti M, et al (1997). Fas-Fas ligand-based interactions between tumor cells and tumor-specifific cytotoxic T lymphocytes: a lethal two-way street. Blood, 90, 1952-9.
27. Zhou JH, Chen HZ, Ye F, et al (2006). Fas-mediated pathway and apoptosis in normal cervix, cervical intraepithelial neoplasia and cervical squamous cancer. Oncol Rep, 16, 307-11.
28. Zielińska K, Kozlowska K, Cichorek M, et al (2008). Fas and FasL expression on cells of two transplantable melanoma lines according to their different biological properties. Folia Histochem Cytobiol, 46, 337-43.